APA (7th ed.) Citation

Loblaw, D., Quon, H., Ong, A., Alayed, Y., Cheung, P., Chu, W., . . . Deabreu, A. (2019). Accelerating Prostate Stereotactic Ablative Body Radiotherapy (SABR): Efficacy and Toxicity of a Randomized Phase II Study of 11 Versus 29 Days Overall Treatment Time (PATRIOT Study; ClinicalTrials.gov NCT01423474). International Journal of Radiation Oncology, Biology, Physics, 105, S56. https://doi.org/10.1016/j.ijrobp.2019.06.491

Chicago Style (17th ed.) Citation

Loblaw, D.A, et al. "Accelerating Prostate Stereotactic Ablative Body Radiotherapy (SABR): Efficacy and Toxicity of a Randomized Phase II Study of 11 Versus 29 Days Overall Treatment Time (PATRIOT Study; ClinicalTrials.gov NCT01423474)." International Journal of Radiation Oncology, Biology, Physics 105 (2019): S56. https://doi.org/10.1016/j.ijrobp.2019.06.491.

MLA (9th ed.) Citation

Loblaw, D.A, et al. "Accelerating Prostate Stereotactic Ablative Body Radiotherapy (SABR): Efficacy and Toxicity of a Randomized Phase II Study of 11 Versus 29 Days Overall Treatment Time (PATRIOT Study; ClinicalTrials.gov NCT01423474)." International Journal of Radiation Oncology, Biology, Physics, vol. 105, 2019, p. S56, https://doi.org/10.1016/j.ijrobp.2019.06.491.